Endocyte's $2.1B Sale To Novartis 'Unfair' To Investors: Suit
Cancer treatment company Endocyte Inc. and its directors omitted crucial information from a proxy statement and undervalued the business in its $2.1 billion acquisition by Novartis AG, according to an investor...To view the full article, register now.
Already a subscriber? Click here to view full article